Aceto has announced its acquisition of a majority stake in Finar, a manufacturer, supplier, and distributor of pharmaceutical excipients, lab chemicals, aquaculture inputs, and food grade additives. The acquisition will expand Aceto’s its manufacturing footprint, R&D capabilities, and quality expertise.
Finar manufactures quality pharma ingredients including GMP/pharma grade solvents, advanced intermediates, and GMP excipients used in both small and large molecule applications. It also provides customers regulatory & documentation support including drug master filing and has an R&D team with experience developing excipients for complex formulations.
“We are excited to bring together Finar and Aceto to give customers of both companies more solutions to support their supply chains globally,” said Gilles Cottier, CEO of Aceto. “With the Finar team’s help, we continue to strengthen our manufacturing expertise and expand our product offerings for the pharmaceutical, biopharmaceutical, and vaccine end markets.”
“We live by our motto of consistently providing customers high-quality products and exceeding their expectations,” said Amit Maheshwari, CEO of Finar. “Both Finar and Aceto create long-term relationships with customers by providing best-in-class customer service and treating each customer with integrity and respect. These attributes are an important part of our company culture and we appreciate that Aceto shares this business philosophy. We look forward to providing our combined customers with access to our manufacturing expertise and diversified product portfolio.”
Aceto will continue to support Finar’s manufacturing facilities and offices in India.
